Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nakane, M.
Right arrow Articles by Ogata, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakane, M.
Right arrow Articles by Ogata, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1449-1450, 2003
© 2003 European Society for Medical Oncology

Letters to the Editor

Successful treatment of malignant pheochromocytoma with combination chemotherapy containing anthracycline

M. Nakane1, S. Takahashi*,1, I. Sekine2, I. Fukui3, M. Koizumi4, K. Kage2, Y. Ito1, K. Aiba1, N. Horikoshi1, K. Hatake1, Y. Ishikawa5 and E. Ogata2

1 Department of Medical Oncology, 2 Department of Internal Medicine, 3 Department of Urology, 4 Department of Radiology, 5 Department of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

*E-mail: stakahas@jfcr.or.jp

The first 10% of the full text of this article appears below.

Malignant pheochromocytomas are rare, accounting for ~10% of all cases of pheochromocytoma. The prognosis is poor because of local recurrence or widespread metastasis [1]. To date, there has been no established chemotherapy for malignant pheochromocytoma. A conventional CVD regimen (consisting of cyclophosphamide, vincristine and dacarbazine) may reduce tumors, but remission is short [2]. Thus, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K.-S. Park, J.-L. Lee, H. Ahn, J.-M. Koh, I. Park, J.-S. Choi, Y. R. Kim, T. S. Park, J.-H. Ahn, D. H. Lee, et al.
Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma
Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 327 - 331.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Joshua, S. Ezzat, S. L. Asa, A. Evans, R. Broom, M. Freeman, and J. J. Knox
Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma
J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 5 - 9.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu
Pheochromocytoma: Current Approaches and Future Directions
Oncologist, July 1, 2008; 13(7): 779 - 793.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert
Current Treatment of Malignant Pheochromocytoma
J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225.
[Abstract] [Full Text] [PDF]